JP2005535664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535664A5 JP2005535664A5 JP2004519990A JP2004519990A JP2005535664A5 JP 2005535664 A5 JP2005535664 A5 JP 2005535664A5 JP 2004519990 A JP2004519990 A JP 2004519990A JP 2004519990 A JP2004519990 A JP 2004519990A JP 2005535664 A5 JP2005535664 A5 JP 2005535664A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- receptor antagonist
- glucocorticoid receptor
- patient
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 28
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 claims 13
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims 12
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 150000003431 steroids Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- -1 dimethylaminophenyl moiety Chemical group 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 229960003248 mifepristone Drugs 0.000 claims 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- YWROELXZPBSUCO-IYXRBSQSSA-N (2r)-1,2,3,4,4a,4b,5,6-octahydrophenanthrene-2,7-diol Chemical compound C12CCC(O)=CC2=CC=C2C1CC[C@@H](O)C2 YWROELXZPBSUCO-IYXRBSQSSA-N 0.000 claims 1
- ZCAUIZYRNPHJJO-CAMMJAKZSA-N (8s,10s,13s,14s)-10,13-dimethyl-1,2,6,7,8,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]12)CC3=CC(=O)CC[C@]3(C)C1=CC[C@@]1(C)[C@H]2CCC1 ZCAUIZYRNPHJJO-CAMMJAKZSA-N 0.000 claims 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000037262 Hepatitis delta Diseases 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39366002P | 2002-07-02 | 2002-07-02 | |
| PCT/US2003/021245 WO2004004653A2 (en) | 2002-07-02 | 2003-07-02 | Methods for treating psychosis associated with interferon-alpha therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535664A JP2005535664A (ja) | 2005-11-24 |
| JP2005535664A5 true JP2005535664A5 (https=) | 2006-10-26 |
Family
ID=30115622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519990A Pending JP2005535664A (ja) | 2002-07-02 | 2003-07-02 | インターフェロン−α治療に関連した精神病を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8476254B2 (https=) |
| EP (1) | EP1534299A4 (https=) |
| JP (1) | JP2005535664A (https=) |
| CN (1) | CN1665515A (https=) |
| CA (1) | CA2491296C (https=) |
| WO (1) | WO2004004653A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097606B2 (en) | 2003-07-23 | 2012-01-17 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of catatonia |
| AU2008211613B2 (en) | 2007-02-02 | 2013-05-23 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| EP1987814A1 (en) * | 2007-04-30 | 2008-11-05 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
| US8710035B2 (en) * | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| WO2012106514A2 (en) | 2011-02-03 | 2012-08-09 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| WO2017023694A1 (en) * | 2015-08-03 | 2017-02-09 | Pop Test Oncology Llc | Pharmaceutical compositions and methods |
| MX2019011543A (es) | 2017-03-31 | 2019-12-16 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical. |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11464764B2 (en) | 2018-12-19 | 2022-10-11 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| WO2021242912A1 (en) | 2020-05-27 | 2021-12-02 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| KR20250073629A (ko) | 2022-10-06 | 2025-05-27 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제의 제형 |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| AU5374798A (en) | 1996-12-05 | 1998-06-29 | Bio-Technology General Corporation | Uses of oxandrolone |
| AU747956B2 (en) * | 1997-10-06 | 2002-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| IL139672A (en) * | 1998-05-15 | 2005-11-20 | Univ Leland Stanford Junior | Glucocorticoid receptor antagonists for the tretment of dementia |
| WO2000021565A1 (en) * | 1998-10-13 | 2000-04-20 | Du Pont Pharmaceuticals Company | Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
| OA11716A (en) | 1998-11-24 | 2005-01-25 | Hollis Eden Pharmaceuticals | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatmentof hepatitis C virus and other togaviruses. |
| US6340696B1 (en) * | 1999-03-31 | 2002-01-22 | The Procter & Gamble Company | Viral treatment |
| US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| WO2001081359A1 (en) * | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
-
2003
- 2003-07-02 JP JP2004519990A patent/JP2005535664A/ja active Pending
- 2003-07-02 EP EP03751785A patent/EP1534299A4/en not_active Withdrawn
- 2003-07-02 CN CN038158116A patent/CN1665515A/zh active Pending
- 2003-07-02 WO PCT/US2003/021245 patent/WO2004004653A2/en not_active Ceased
- 2003-07-02 US US10/519,008 patent/US8476254B2/en active Active
- 2003-07-02 CA CA2491296A patent/CA2491296C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535664A5 (https=) | ||
| CA2491296A1 (en) | Methods for treating psychosis associated with interferon-.alpha. therapy | |
| JP2001518509A5 (https=) | ||
| JP2006508951A5 (https=) | ||
| JP2006507311A5 (https=) | ||
| ES2219673T3 (es) | Dosificado posologico ciclofasico de hormonas que contienen una antiprogestina y una progestina. | |
| JP2019163318A5 (https=) | ||
| JP2009504157A5 (https=) | ||
| JP2006527193A5 (https=) | ||
| RU2009120528A (ru) | Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла | |
| JP2010508275A5 (https=) | ||
| CN1905885A (zh) | 包含雌激素和孕激素的延长应用组合 | |
| JP2002515453A5 (https=) | ||
| CA2504697A1 (en) | Methods for treating migraine | |
| JP2024129140A5 (https=) | ||
| JP2010507685A5 (https=) | ||
| JP2003505336A5 (https=) | ||
| RU2020113341A (ru) | Способ и композиция для лечения вирусной инфекции | |
| JP2005519893A5 (https=) | ||
| AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
| KR20110053327A (ko) | 텔라프레비르 투여 방식 | |
| CA2459033A1 (en) | Methods for inhibiting cognitive deterioration in adults with down's syndrome | |
| JP2003527342A5 (https=) | ||
| JP2007505829A5 (https=) | ||
| HRP20140257T4 (hr) | Uporaba ciklesonida za liječenje bolesti dišnih puteva |